Portfolio Holdings Detail for ISIN IE00BDZVHG35
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) |
| Issuer | Blackrock |
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
| ETF Ticker | BTEE(USD) LSE |
| ETF Ticker | BTEE.L(GBP) LSE |
Holdings detail for ACRS
| Stock Name | Aclaris Therapeutics Inc |
| Ticker | ACRS(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US00461U1051 |
| LEI | 5493000B2LQ9QTW1DF52 |
Show aggregate ACRS holdings
News associated with ACRS
- Reviewing Aclaris Therapeutics (NASDAQ:ACRS) and GelStat (OTCMKTS:GSAC)
- Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and GelStat (OTCMKTS:GSAC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Analyst Recommendations This is a summary of current […] - 2025-09-04 02:46:48
- Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $8.71
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month […] - 2025-08-04 02:26:49
- Alps Advisors Inc. Buys 21,022 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Alps Advisors Inc. increased its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 36.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,782 shares of the biotechnology company’s stock after buying an additional 21,022 shares during the […] - 2025-07-18 04:50:52
- Head-To-Head Survey: Aclaris Therapeutics (NASDAQ:ACRS) vs. Plus Therapeutics (NASDAQ:PSTV)
- Plus Therapeutics (NASDAQ:PSTV – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Institutional & Insider Ownership 3.3% of Plus […] - 2025-07-10 03:07:05
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of “Buy” from Brokerages
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 […] - 2025-07-07 03:17:01
- Wedbush Reaffirms “Outperform” Rating for Aclaris Therapeutics (NASDAQ:ACRS)
- Wedbush reissued their outperform rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report released on Monday morning,RTT News reports. The brokerage currently has a $8.00 price objective on the biotechnology company’s stock. Other equities research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued […] - 2025-06-24 03:12:46
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Buy” by Brokerages
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has earned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among […] - 2025-06-12 04:56:58
- Squarepoint Ops LLC Has $726,000 Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Squarepoint Ops LLC boosted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 108.3% during the fourth quarter, Holdings Channel reports. The fund owned 292,892 shares of the biotechnology company’s stock after acquiring an additional 152,312 shares during the period. Squarepoint Ops LLC’s holdings in Aclaris Therapeutics were worth $726,000 at […] - 2025-06-03 05:05:01
- Jefferies Financial Group Inc. Increases Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Jefferies Financial Group Inc. increased its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 253.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 40,700 shares of the biotechnology company’s stock after acquiring an additional 29,200 shares during the quarter. Jefferies Financial Group […] - 2025-06-02 05:40:59
- Wedbush Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)
- Equities researchers at Wedbush assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $8.00 price target on the biotechnology company’s stock. Wedbush’s price target points to a potential upside of 447.95% from the company’s current […] - 2025-05-30 02:16:45
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Lowered by Two Sigma Advisers LP
- Two Sigma Advisers LP reduced its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 24.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 977,400 shares of the biotechnology company’s stock after selling 324,100 shares during the […] - 2025-05-29 06:22:53
- Man Group plc Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Man Group plc acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund acquired 53,534 shares of the biotechnology company’s stock, valued at approximately $133,000. Other large investors have also recently added to or reduced their stakes in the company. ExodusPoint Capital […] - 2025-05-29 05:40:58
- Millennium Management LLC Sells 1,046,551 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Millennium Management LLC reduced its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 34.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,959,047 shares of the biotechnology company’s stock after selling 1,046,551 shares during the quarter. Millennium Management LLC’s holdings in Aclaris Therapeutics […] - 2025-05-29 04:52:50
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $10.00 Consensus Target Price from Analysts
- Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 […] - 2025-05-23 04:30:49
- Graham Capital Management L.P. Takes $35,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Graham Capital Management L.P. bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor bought 14,172 shares of the biotechnology company’s stock, valued at approximately $35,000. A number of other large investors also recently modified their holdings of ACRS. ExodusPoint Capital Management LP […] - 2025-05-20 05:09:15
- Schonfeld Strategic Advisors LLC Invests $327,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Schonfeld Strategic Advisors LLC acquired a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 131,895 shares of the biotechnology company’s stock, valued at approximately $327,000. A number of other hedge […] - 2025-05-13 05:31:18
- Aclaris Therapeutics (NASDAQ:ACRS) Price Target Lowered to $9.00 at Scotiabank
- Aclaris Therapeutics (NASDAQ:ACRS – Free Report) had its price target reduced by Scotiabank from $15.00 to $9.00 in a report released on Friday morning,Benzinga reports. They currently have a sector outperform rating on the biotechnology company’s stock. Several other research analysts have also recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of […] - 2025-05-12 02:58:53
- Geode Capital Management LLC Cuts Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Geode Capital Management LLC decreased its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 6.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 789,597 shares of the biotechnology company’s stock after selling 56,849 shares during the period. Geode […] - 2025-04-30 04:36:52
- Aclaris Therapeutics Appoints Jesse Hall As CMO
- (RTTNews) - Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company, on Tuesday announced the appointment of Jesse Hall as Chief Medical Officer. The transition is effective May 1. - 2025-04-29 08:47:49
- ExodusPoint Capital Management LP Invests $26,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- ExodusPoint Capital Management LP purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,637 shares of the biotechnology company’s stock, valued at approximately $26,000. A number of other […] - 2025-04-15 04:38:56
- Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 26.7%
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 6,030,000 shares, an increase of 26.7% from the February 28th total of 4,760,000 shares. Currently, 9.0% of the company’s stock are sold short. Based on an average trading volume […] - 2025-04-03 02:25:04
- Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price target […] - 2025-03-07 04:44:45
- Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to “Strong-Buy” at Cantor Fitzgerald
- Cantor Fitzgerald upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2025 earnings at ($0.54) EPS. Several other equities research analysts also recently issued reports on ACRS. HC Wainwright raised Aclaris Therapeutics from […] - 2025-03-07 04:10:47
- Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.00
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target […] - 2025-02-14 06:22:49
- Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by StockNews.com to “Sell”
- StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a hold rating to a sell rating in a report published on Saturday. Several other equities research analysts have also commented on the stock. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price […] - 2025-02-11 04:13:09
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ACRS holdings
| Date | Number of ACRS Shares Held | Base Market Value of ACRS Shares | Local Market Value of ACRS Shares | Change in ACRS Shares Held | Change in ACRS Base Value | Current Price per ACRS Share Held | Previous Price per ACRS Share Held |
|---|
| 2025-12-24 (Wednesday) | 72,019 | USD 218,938 | USD 218,938 | 0 | USD 10,083 | USD 3.04 | USD 2.9 |
| 2025-12-23 (Tuesday) | 72,019 | USD 208,855 | USD 208,855 | -2,100 | USD -18,690 | USD 2.9 | USD 3.07 |
| 2025-12-22 (Monday) | 74,119 | USD 227,545 | USD 227,545 | 0 | USD -5,189 | USD 3.07 | USD 3.14 |
| 2025-12-19 (Friday) | 74,119 | USD 232,734 | USD 232,734 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ACRS by Blackrock for IE00BDZVHG35
Show aggregate share trades of ACRS| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-12-23 | SELL | -2,100 | 3.060 | 2.780 | 2.808 | USD -5,897 | 2.91 Profit of 224 on sale |
| 2024-11-18 | SELL | -1,800 | 3.140 | 3.540 | 3.500 | USD -6,300 | 1.88 Loss of -2,920 on sale |
| 2024-11-08 | SELL | -120 | 2.640 | 2.670 | 2.667 | USD -320 | 1.77 Loss of -107 on sale |
| 2024-10-21 | SELL | -120 | 1.210 | 1.220 | 1.219 | USD -146 | 0.00 Loss of -146 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ACRS
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 211,180 | 0 | 344,530 | 61.3% |
| 2025-09-18 | 203,513 | 0 | 547,693 | 37.2% |
| 2025-09-17 | 83,704 | 0 | 261,557 | 32.0% |
| 2025-09-16 | 140,340 | 0 | 388,537 | 36.1% |
| 2025-09-15 | 195,725 | 2,800 | 565,823 | 34.6% |
| 2025-09-12 | 275,367 | 0 | 1,336,498 | 20.6% |
| 2025-09-11 | 249,156 | 3,500 | 1,404,327 | 17.7% |
| 2025-09-10 | 165,844 | 401 | 952,757 | 17.4% |
| 2025-09-09 | 214,804 | 0 | 389,846 | 55.1% |
| 2025-09-08 | 172,311 | 0 | 269,855 | 63.9% |
| 2025-09-05 | 154,208 | 20,246 | 321,888 | 47.9% |
| 2025-09-04 | 154,102 | 0 | 355,826 | 43.3% |
| 2025-09-03 | 133,166 | 100 | 364,833 | 36.5% |
| 2025-09-02 | 180,787 | 2,000 | 450,420 | 40.1% |
| 2025-08-29 | 109,125 | 9,900 | 377,110 | 28.9% |
| 2025-08-28 | 43,173 | 0 | 119,013 | 36.3% |
| 2025-08-27 | 124,053 | 0 | 246,332 | 50.4% |
| 2025-08-26 | 88,869 | 0 | 170,519 | 52.1% |
| 2025-08-25 | 65,583 | 0 | 241,781 | 27.1% |
| 2025-08-22 | 60,284 | 0 | 230,654 | 26.1% |
| 2025-08-21 | 46,861 | 0 | 127,536 | 36.7% |
| 2025-08-20 | 43,314 | 3 | 172,407 | 25.1% |
| 2025-08-19 | 143,064 | 101 | 498,785 | 28.7% |
| 2025-08-18 | 200,322 | 2,500 | 576,938 | 34.7% |
| 2025-08-15 | 144,736 | 6,241 | 733,262 | 19.7% |
| 2025-08-14 | 48,876 | 0 | 210,245 | 23.2% |
| 2025-08-13 | 183,144 | 4,835 | 835,344 | 21.9% |
| 2025-08-12 | 89,775 | 2,738 | 293,205 | 30.6% |
| 2025-08-11 | 131,150 | 564 | 727,766 | 18.0% |
| 2025-08-08 | 146,910 | 0 | 480,718 | 30.6% |
| 2025-08-07 | 102,697 | 0 | 334,024 | 30.7% |
| 2025-08-06 | 91,055 | 27 | 260,163 | 35.0% |
| 2025-08-05 | 61,044 | 0 | 164,418 | 37.1% |
| 2025-08-04 | 122,978 | 0 | 312,554 | 39.3% |
| 2025-08-01 | 236,304 | 803 | 465,473 | 50.8% |
| 2025-07-31 | 174,701 | 314 | 546,940 | 31.9% |
| 2025-07-30 | 821,762 | 37,249 | 2,901,034 | 28.3% |
| 2025-07-29 | 108,569 | 0 | 341,409 | 31.8% |
| 2025-07-28 | 140,856 | 0 | 344,640 | 40.9% |
| 2025-07-25 | 74,323 | 0 | 139,815 | 53.2% |
| 2025-07-24 | 275,627 | 0 | 598,969 | 46.0% |
| 2025-07-23 | 38,652 | 0 | 145,355 | 26.6% |
| 2025-07-22 | 70,100 | 100 | 225,895 | 31.0% |
| 2025-07-21 | 202,734 | 0 | 523,199 | 38.7% |
| 2025-07-18 | 138,276 | 1,000 | 321,284 | 43.0% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy